Last Updated: 03/11/24
Preclinical Development Stage NExT Projects
NExT projects in preclinical development are supported and managed through the NCI’s Developmental Therapeutics Program for small molecules and Biopharmaceutical Development Program for biologics.
| Applicant | Institute | Project |
|---|---|---|
| Stephen Fesik | Vanderbilt University | Discovery of small molecule inhibitors of WDR5 |
| Tin Tin Su | SuviCa | Developing a small molecule inhibitor of eEF2 |
| Donald Kufe | Dana Farber Cancer Institute | Targeting MUC1-C with an ADC for Treatment of Aggressive Recalcitrant Cancers |
| Tony Giordano | Abcon Therapeutics, Inc. | ATX101 for Treating T-cell Lymphoma |
| Jan Schnitzer | Proteogenomics Research Institute for Systems Medicine | Developing hAnnA1-based immunoconjugates for cancer detection and treatment |
| Kate Rittenhouse | For-Robin | hJAA-F11, a Humanized Anti-Thomsen Friedenreich Antibody for Cancer Therapy |
| Yuesheng Zhang | Virginia Commonwealth University/Roswell Park | PEPDG278D for Treatment of HER2-positive Breast Cancer |
| Crystal Mackall | Stanford University | CAR T Cells targetig Glypican-2 (GPC2) for children and young adults with recurrent and refractory neuroblastoma and medulloblatoma |
| John Lee | Fred Hutchinson Cancer Research Center | STEAP1 chimeric antigen receptor T cell therapy for prostate cancer |
| Sidi Chen | Yale | Translating a metabolic enhancer for CAR-T towards IND-enabling stage |
| Kazusa Ishii | NCI/CCR | Clinical-Grade Vector Manufacturing for CD22 TCR-T Cell Therapy |
| Michael Demetriou | University California, Irvine | Immunotherapy targeting abnormal N-glycans for solid cancer |
| Jennifer Grandis | University California, San Francisco | Development of a Cyclic STAT3 Decoy Oligonucleotide (CS3D) |
| Jing Wu | NCI/CCR | [1-13C]-a-ketoglutarate as an Imaging Probe in IDH-mutant Gliomas |
| Patrick Grohar | Childrens Hospital of Philadelphia | Development of AIT-102 (EC-8042) as a Targeted therapy for Ewing Sarcoma and Rhabdoid Tumor |
| Judith Leopold | Mekanistic Therapeutics | MTX-531, a first-in-class dual inhibitor of PI3K and EGFR for targeting solid tumors |
| Alan D'Andrea | Dana Farber Cancer Institute | Polymerase Theta Inhibitor Overcomes PARP Inhibitor Resistance |
| Ernesto Guccione | Mt. Sinai | IND-enabling studies for WNTinib, a novel selective therapeutic for CTNNB1 mutant hepatocellular carcinoma |
| Mark Suto | Southern Research Institute | DNA Methyltransferase_Td-Cyd |
| Mark Suto | Southern Research Institute | DNA Methyltransferase_Aza-TdC |
| Faller, Douglas | Takeda Pharmaceuticals | TAK-243, a small molecule UAE inhibitor |
| Linda Vahdat | Dartmouth University | Phase 2 randomized, placebo-controlled study of ammounium tetrathiomolybdate in TNBC |
| Leigh, Bryan | Tracon Pharmaceuticals | Development of TRC102 as a Novel Inhibitor of Base Excision Repair |